Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q4 FY19 results · Jan–Mar 2019
Jubilant Pharmova reported revenue from operations of ₹2,385.58 crore and net loss of ₹100.65 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,385.58 | — | — | 2,377.10 | +0.4% |
| Other income | (6.58) | — | — | 29.02 | Turned loss |
| Total income | 2,379.00 | — | — | 2,406.12 | −1.1% |
| Profit before tax | (39.98) | — | — | 355.61 | Turned loss |
| Net profit for the period | (100.65) | — | — | 267.52 | Turned loss |
| Attributable to shareholders of the company | (99.29) | — | — | 260.84 | Turned loss |
| EPS, basic (₹) | (6.38) | — | — | 16.74 | Turned loss |
| Net margin (%) | -4.2 | — | 11.3 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 865.12 | — | — | 859.58 | +0.6% |
| Other income | 4.83 | — | — | 4.96 | −2.6% |
| Total income | 869.95 | — | — | 864.54 | +0.6% |
| Profit before tax | 6.39 | — | — | 52.38 | −87.8% |
| Net profit for the period | 7.44 | — | — | 36.70 | −79.7% |
| EPS, basic (₹) | 0.47 | — | — | 2.30 | −79.6% |
| Net margin (%) | 0.9 | — | 4.3 |
Consolidated
- Filed with BSE
- 18 May 2019, 12:13 IST
- Board meeting
- 17 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2019, 12:13 IST
- Board meeting
- 17 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE